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Abstract
Background: Generation of robust cell-mediated immune responses at mucosal surfaces while reducing overall
inflammation is a primary goal for vaccination. Here we report the use of a recombinant nanoparticle as a vaccine
delivery platform against mucosal infections requiring T cell-mediated immunity for eradication.
Methodology/Principal Findings: We encapsulated an immunogenic protein, the major outer membrane protein (MOMP)
of Chlamydia muridarum, within hollow, vault nanocapsules (MOMP-vaults) that were engineered to bind IgG for enhanced
immunity. Intranasal immunization (i.n) with MOMP-vaults induced anti-chlamydial immunity plus significantly attenuated
bacterial burden following challenge infection. Vault immunization induced anti-chlamydial immune responses and
inflammasome formation but did not activate toll-like receptors. Moreover, MOMP-vault immunization enhanced microbial
eradication without the inflammation usually associated with adjuvants.
Conclusions/Significance: Vault nanoparticles containing immunogenic proteins delivered to the respiratory tract by the
i.n. route can act as ‘‘smart adjuvants’’ for inducing protective immunity at distant mucosal surfaces while avoiding
destructive inflammation.
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Introduction
Mucosal immune responses provide superior protection against
disease but there are currently no FDA-approved adjuvants
capable of stimulating cell-mediated immune responses within
mucosal tissues [1]. Perhaps one reason is because mucosal
immune responses are generated by stimulating mucosal surfaces.
However, mucosal surfaces are hostile environments and immu-
nogenic proteins require added protection for delivery to dendritic
cells and induction of immunity [2]. We hypothesized that
recombinant vaults could provide such protection by encapsulat-
ing an antigen and preserving its functional characteristics even
within cells [3]. Vaults are ubiquitous, large ribonucleoprotein
particles found in nearly all eukaryotic cells including dendritic
cells, the endometrium and lung [4]. The vault has a mass of
12.961 MDa [5] and a crystal structure at 3.5 Angstrom
resolution revealed overall dimensions of approximately 400 A˚
wide and 700 A˚ long [6]. Cellular functions of vaults are currently
unknown but recent work has found that endogenous vaults may
concentrate in lipid rafts and play a role in the uptake of bacteria
in the respiratory mucosa [7].
Native vaults are composed of multiple copies of three protein
species and several copies of a small untranslated RNA. The most
abundant protein, the 97 kDa major vault protein (MVP), is
present in 96 copies per vault and forms the barrel-shaped
structure of the vault particle [8]. The MVP sequence alone
encodes all the needed structural information that enables the
protein to self-assemble and form a recombinant vault nanopar-
ticle using the baculovirus system [9]. The internal cavity of the
recombinant vault is large enough to accommodate multiple
immunogenic proteins. Because vaults are the size of small
microbes, a vault particle containing an immunogenic protein
should be readily phagocytosed by dendritic cells. Further,
recombinant vaults containing proteins are straightforward to
produce making vaults a viable vaccine delivery scaffold if they
prove facile for generating mucosal immunity.
Mucosal immune responses are optimally produced by
stimulating mucosal associated lymphoid tissue. For instance,
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delivery of immunogenic proteins to nasal surfaces stimulates the
induction of immune responses within nasal associated lymphoid
tissue (NALT) [10]. Mucosal immune surfaces are interconnect-
ed and stimulation of the inductive site in one mucosal surface,
produces an immune response at distant mucosal surfaces [11].
In particular, stimulation of the nasal mucosa induces the
appearance of immune cells and antibodies in vaginal surfaces
[12]. To test the utility of vaults as mucosal vaccine delivery
platforms, we chose an infection that relies on cell-mediated
mucosal immune responses for elimination and is a significant
burden on health care; Chlamydia trachomatis infection. Vaginal
delivery of the mouse adapted strain of C. trachomatis, C.
muridarum, induces a local sexually transmitted infection (STI)
similar to human chlamydial STI [13]. C. trachomatis is a
prominent cause of STI, with approximately 92 million cases
occurring annually [14] and is an instigator of female
reproductive dysfunction [15]. T helper immune cells (Th1)
must be present within vaginal tissues in order to eradicate
infection [16]. However, a vaccine has not yet been produced
which induces sizeable Th1 immune responses in mucosal
tissues. Therefore, an ideal vaccine would elicit a local anti-
chlamydial Th1 cell response in the reproductive mucosa.
Materials and Methods
Ethics Statement
All experimental procedures using animals were approved by the
UCLA Institutional Animal Care and Use Committee and
conducted according to relevant national and international
guidelines. All procedures were designed to provide the best possible
scientific methodologies available. Since there are no less painful/
distressful options available, the techniques have been refined to
provide for maximum comfort/minimal stress to the animals. The
animals were monitored for pain/distress by exhibiting signs of
agitation (licking, biting or guarding the vaginal region), failure to
groom, loss of appetite, or marked weight loss (.10%). The
Attending Veterinarian was consulted for his/her recommendation
for prophylactic treatment when these signs were observed.
MOMP-mINT Recombinant Vaults
Recombinant baculoviruses were generated using the Bac-to-
Bac protocol (Invitrogen, Carlsbad, CA). The 366 amino acid
coding region of MOMP (without the signal sequence) was fused
to the minimal interaction domain (mINT) derived from VPARP
(amino acids 1563–1724) by PCR ligation using the following
primers: MOMP-mINT reverse- TCCTGCCAGTGTTG-
TGTGCAGAAACGGAACTGAGCATTTAC; MOMP-mINT
forward- GTAAATGCTCAGTTCCGTTTCTGCACACAACA-
CTGGCAGGA; mINT reverse- GGGCTCGAGTTAGCCTT-
GACTGTAATGGAG. Two PCR reactions were carried out with
the first using a standard T7 primer forward x MOMP-mINT
reverse using the MOMP in pcDNA3 as the template. The second
PCR reaction used the MOMP-mINT forward x mINT reverse
using mINT in pET28 as the template. The PCR reactions were
purified on aQiagen column and a second round of PCRwas carried
out using the T7 primer forward x mINT reverse. The resultant PCR
product containing the fused MOMP-mINT was purified on a
Qiagen column, digested with Bam H1 and Xho I, gel purified, and
ligated to pFastBac to form a pFastBac vector containing MOMP-
mINT. Construction of GL (enhanced green fluorescent protein)-
INT in pFastBac has been described previously [3].
Sf9 cells were infected with MOMP-mINT, GL-INT, cp-MVP-
z, or cp-MVP recombinant baculoviruses at a multiplicity of
infection (MOI) of 0.01 for approximately 65 h and then pelleted
and lysed on ice in buffer A [50 mM Tris-HCl (pH 7.4), 75 mM
NaCl, and 0.5 mM MgCl2] with 1% Triton X-100, 1 mM
dithiothreitol, 0.5 mM PMSF, and protease inhibitor cocktail
(2 mg/ml aprotinin, 0.5 mM benzamidine, 2 mg/ml chymostatin,
5 mM leupeptin, 5 mM pepstatin) (Sigma). Lysates containing cp-
MVP-z vaults were mixed with lysates containing either MOMP-
mINT or GL-INT and were incubated on ice for 30 min to allow
the INT fusion proteins to package inside of vaults. Recombinant
vaults were purified as previously described [9,17,18] and
resuspended in 100–200 ml of sterile phosphate buffered saline.
The protein concentration was determined using the BCA assay
(Pierce) and sample integrity was analyzed by negative stain
electron microscopy and SDS-PAGE with Coomassie staining.
Gel Electrophoresis and Immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was
performed using the discontinuous buffer system and 10–12.5%
acrylamide gels. Protein samples of MoPn or MOMP-vaults or
whole lysates from dendritic cells were transferred to an
Immobilon-P transfer membrane (Millipore) and blocked with
5% (wt/vol) nonfat dry milk in PBS-0.1% Tween 20 (PBS-T).
Membranes were individually incubated for 1 h either with
antiserum raised against Live CT (1:500), MOMP-vaults (1:500),
GL-vaults (1:500), mouse IgG3 anti-MoPn-40 (1:5000), mouse
anti-MVP (1:500, MAB 1023, Santa Cruz Biotechnology Inc,
Santa Cruz, CA) or polyclonal rabbit IL-1b (1:250, sc-7884, Santa
Cruz Biotechnology) followed by a 1 h incubation with the
appropriate horseradish conjugate (1:5,000, Amersham Bioscienc-
es, Piscataway, NJ). Bound conjugates were detected with
SuperSignal West Dura extended duration substrate (Pierce
Biotechnology Inc, Thermo Scientific, Rockford, IL) and an
Alpha Innotech Fluorchem 8000 imager.
Anti-vault ELISA Assay
Purified vaults from cp-MVP-z or cp-MVP infected Sf9 cells were
diluted to 2 mg/ml in phosphate buffered saline (PBS) and applied to
a 96-well dish by serially diluting from 100 ng to 12.5 ng per well (all
assays were carried out minimally in duplicate). The plates were
incubated at 4uC overnight to allow binding. Unoccupied sites were
blocked with 5% BSA in PBS containing 0.05% Tween 20 (PBST)
for 1 h at 25uC. After removal of the blocking solution the wells were
washed 3 times for 5 min each at 25uC with PBST. Primary
antibody (100 ml/well) of either purified mIgG (1 mg/ml, Sigma-
Aldrich, St. Louis, MO) or mIgA, kappa-TEPC 15 (2 mg/ml, Sigma-
Aldrich) diluted into PBST was applied for 1 h at 25uC. Following
removal of the primary antibody the wells were washed as described
above. A peroxidase conjugated sheep anti-mouse HRP antibody
(1:1000, GE Healthcare, Piscataway, NJ) in PBST was applied for
1 h at 25uC. After washing the plates, a substrate-chromogen was
added (DakoCytomation, Glostrup, Denmark) and developed for
15 min. The reaction was stopped by the addition of 1N H2SO4.
The optical densities were read at 450 nm with a microplate reader
(model 550; Bio-Rad, Hercules, CA).
Dendritic cell Uptake Assay and Flow cytometric analysis
Immature bone marrow dendritic cells (BMDC) from 12 wk old
C57BL/6 mice were generated as previously described [19]. The
cells were enriched by positive selection using magnetic microbeads
conjugated to anti-mouse CD11c mAb (EasySep, STEMCELL
Technologies, Inc., Vancouver, BC) and assessed for maturity by
measuring expression of MHC class II (anti-IAb) and CD40
(eBioscience). Purity of approximately 94% was assessed by flow
cytometric analyses acquired on a FACSCalibur flow cytometer with
CellQuest Pro software (Becton Dickinson, San Jose, Calif.). BMDC
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(16106) were incubated with media, GL-vaults (500 mg) or FITC-
dextran (250 mg) (Sigma) for 30–60 minutes at 37uC. These cells
were collected, stained with CD11c-PE, a cell surface marker of
murine dendritic cells and at least 10,000 cells, based on forward and
90u light scatter properties, were analyzed by flow cytometry. Flow
cytometric analysis was performed using FCS Express 2.0 (DeNovo
Software, Los Angeles, CA).
Luminex Suspension Bead Array
Cytokines were measured in the supernates of BMDC or genital
tract (GT) homogenates by the Mucosal Immunology Core
laboratory at UCLA using the Milliplex Mouse Cytokine/
Chemokine Immunoassay (Millipore Corp, Billerica, MA).
Multiple, cytokine-specific antibodies were combined to use for
the simultaneous measurement of the following mouse cytokines:
IL-1a, IL-1b, IL-4, IL-6, IL-10, 1L-12p70, IFN-c, TNF-a, CCL5
(RANTES), CXCL10 (IP-10) and CXCL2 (MIP-2).
Toll-like receptor (TLR) Ligand Screening
Empty vaults (cp-MVP-z), GL-vaults, and MOMP-vaults were
purified over sucrose gradients by collecting various densities (40, 45
or the interface 40/45) and assessed for potential TLR ligand activity
using the InvivoGen TLR Ligand Screening Service (San Diego,
CA). TLR stimulation was measured in HEK 293 cells stably
transfected with individual plasmids containing mouse TLR 2, 3, 4,
5, 7, and 9 as well as an NF-kB inducible promoter plasmid
expressing the secreted embryonic alkaline phosphatase (SEAP)
reporter gene. Briefly, 10 mg of each vault prep and positive controls
were added to 96-well plates containing 100 ml of reporter cells
(56104/ml). The positive controls employed were TLR2 (heat-killed
Listeria monocytogenes, 108 cells/ml), TLR3 (Poly(I:C) 1 mg/ml),
TLR4 (Escherichia coli K12 LPS, 100 ng/ml), TLR5 (S. typhimur-
ium flagellin, 1 mg/ml), TLR7 (Loxoribine, 1 mM), and TLR9
(CpG ODN 2006, 1 mg/ml). Cultures were incubated for 24 h and
analyzed for NF-kB driven SEAP expression using a substrate
followed by absorbance measurements at 650 nm.
Chlamydia, Immunization and Challenge of mice
Chlamydia muridarum (MoPn) was grown on confluent McCoy cell
monolayers, purified on Renograffin gradients and stored at 270uC
in SPG buffer (sucrose-phosphate-glutamine) as previously described
[20]. Female C57BL/6 mice, 5–6 weeks old (Harlan Sprague-
Dawley, Indianapolis, IN) were housed according to American
Association of Accreditation of Laboratory Animal Care guidelines.
Mice receiving vaults were anesthetized with a mixture of 10%
ketamine plus 10% xylazine and immunized i.n. with 200 mg
MOMP-vaults or 200 mg GL-vaults in 30 ml saline for a total of 3
times every two weeks. As a positive control, a group of mice were
immunized i.n. with a single infection of 103 inclusion-forming units
(IFU) of MoPn as described [21]. Mice were hormonally synchro-
nized by subcutaneous infection with 2.5 mg of medroxyprogester-
one acetate (Depo Provera, Upjohn, Kalamazoo,MI) in 100 ml saline
7 days prior to a vaginal challenge with 1.56105 IFU of C. muridarum
and infection was monitored by measuring infection forming units
(IFU) from cervical–vaginal swabs (Dacroswab Type 1, Spectrum
Labs, Rancho Dominguez, CA) as previously described [20].
Analysis of T-cell responses
Spleens and iliac lymph nodes (ILN) were harvested from
individual mice, dissociated into single-cell suspensions and
stimulated for 4 hours with Phorbol myristate acetate (20 ng/ml),
ionomycin (500 ng/ml) and Brefeldin A (10 ug/ml) at 37uC, 5%
CO2. Following incubation, the cells were collected, washed and
stained for cell surface markers (CD3,CD4) followed by intracellular
cytokine staining (IFNc, IL-4) and at least 50,000 live cells, based on
forward and 90u light scatter properties, were analyzed by flow
cytometry as described above. Genital tract (GT) tissue was
harvested aseptically from mice at various time-points following
intravaginal inoculation with MoPn and divided into cervical-
vaginal region (CV), uterine horns (UH), and oviducts (OD) with the
ovaries removed as described [22]. The samples were homogenized
using a hand-held homogenizer (Omni Intl., Warrenton, VA) on ice
in 2 ml of protease inhibitor buffer (Complete Mini Protease
Inhibitor Cocktail tablets at a proportion of 1 tablet/25 ml PBS,
Roche Diagnostics, Indianapolis, IN). Following homogenation,
aliquots were removed to measure chlamydial burden using IFU
determination as described [20]. The remaining homogenate
samples were centrifuged at 15,0006g for 30 minutes, the
supernatants transferred to clean microcentrifuge tubes and stored
at 70uC until Luminex analysis was performed.
Statistics
Two-way repeated measures (RM) analysis of variance
(ANOVA) was used to determine statistical differences in the level
of infection in the cervical-vaginal swabs (log 10 transformation).
Student’s t-test or one-way ANOVA was used to evaluate antibody
or cytokine levels in tissue homogenates, cell culture supernatants
or serum. The above statistical tests were suggested by and
performed using SigmaStat software based on the distribution of
the data and sample size (Jandel Scientific, San Rafael, CA).
Groups were considered statistically different at p,0.05.
Results
Design of recombinant vault nanoparticles containing
immunogenic proteins
Mucosal immune responses are optimally produced by
stimulating mucosal associated lymphoid tissue (MALT). For
instance, delivery of immunogenic proteins to nasal surfaces
stimulates the induction of immune responses within nasal
associated lymphoid tissue (NALT) [10]. Mucosal immune
surfaces are interconnected and stimulation of the inductive site
in one mucosal surface produces an immune response at distant
mucosal surfaces [11]. In particular, stimulation of the nasal
mucosa induces the appearance of immune cells and antibodies in
vaginal surfaces [12]. We designed vault nanoparticles for use as
mucosal immunogens to vaccinate mice.
Vaults are conserved throughout evolution, found in Trypano-
somes through mammals and are composed of multiple copies of
three protein species and several copies of a small untranslated
RNA. The most abundant protein, the 97 kDa major vault protein
(MVP), is present in multiple copies per vault. Expression of MVP
in insect cells using the baculovirus system results in production of
vault-like particles formed entirely from the expressed MVP,
leading to the conclusion that MVP alone is sufficient to form
vault-like particles. These vaults, which lack the two high
molecular weight vault proteins (TEP1 and VPARP) and the
vault RNA, are less rigid than native vaults [9]. The MVP
molecule was modified for increased stability by the addition of a
cysteine-rich tag (cp-MVP) [23].
Delivery of particles to dendritic cells (DC) through the FcR of
Ig has been proposed as an effective vaccination strategy for
boosting cell-mediated immune responses against C. muridarum
infection and other pathogens [24,25]. Further, Th1 responses
and immunity against chlamydial genital infection were shown to
require the presence of FcR on DC [25]. Cryo-EM and antibody
binding studies have shown that molecules on the C terminus of
A Protective Vault Vaccine
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the MVP are displayed on the outside of the particle at the cap
[26]. We modified vaults by the addition of a 33 aa peptide (z)
derived from staphylococcal protein A to the C-terminus
(hereafter referred to as cp-MVP-z) that binds the Fc portion
of immunoglobulins at a site distinct from binding to the Fc
receptor (FcR) [26]. We tested the ability of vaults expressing
(cp-MVP-z) or lacking (cp-MVP) the Fc binding peptide to
adhere to mouse Ig isotypes which are generally found in nasal
secretions (IgG and IgA) using an ELISA assay. Vaults
containing the ‘‘z’’ peptide markedly bound IgG over vaults
lacking the ‘‘z’’ peptide. In contrast, regardless of whether or not
vaults expressed the ‘‘z’’ peptide, they did not adhere to IgA
(Fig. 1a). Thus, the ‘‘z’’ peptide increases binding of mouse IgG
to cp-MVP-z vaults.
Figure 1. Design of recombinant vault nanoparticles containing immunogenic proteins. (a) ELISA assay configured using vaults with the z
peptide (cp-MVP-z) and without (cp-MVP) reacted with either mouse IgG or IgA. Data points represent duplicates, SD= 0.004–0.034 nm. (b)
Schematic diagram of constructs used to prepare baculovirus recombinant vaults containing MOMP indicating their approximate locations within a
vault. (c) Western blot of high speed pellet extracts of MOMP-vaults (5 mg/lane). Molecular weight markers (lane 1). The gel was probed with a
monoclonal antibody against the VD1 region of MOMP (MoPn-40)(lane 2) or mouse 1023C monoclonal antibody against MVP (lane 3). The size of
MOMP fused to mINT is shown in the box and is approximately 58 kDa. (d) Negative stain EM of cp-MVP and cp-MVP-z/MOMP-mINT recombinant
vaults. Bar, 100 nm.
doi:10.1371/journal.pone.0005409.g001
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Figure 2. Dendritic cells are efficient at incorporating vaults. (a) BMDC (16106) were incubated with media, GL-vaults (500 mg) or FITC-
dextran (250 mg) at 37uC for the indicated times. Cells were stained for a marker on mouse BMDC (CD11c-PE) and analyzed using a flow cytometer. (b)
BMDC (red) incubated as above for 30 min were viewed on a fluorescent microscope (Carl Zeiss, LSM5 Pascal). The fluorescent particles (GL-vaults or
FITC-dextran) appear green and mouse BMDC appear red due to staining with CD11c-PE. Results shown are representative of three experiments.
doi:10.1371/journal.pone.0005409.g002
Figure 3. Vaults which contain proteins initiate dendritic cell maturation. BMDC (16106) were incubated with media alone, empty vaults
(500 mg), GL-vaults (500 mg), MOMP-vaults (500 mg) or the control, LPS (100 ng/ml). Culture supernates were collected 18 hrs later and the indicated
cytokines, (a) IL-12p70, (b) IL-10, (c) CXCL10, (d) TNFa, (e) IL-6 (e), and (f) CXCL2, were measured by Luminex technology. ANOVA (p,0.001) indicated
that the level of cytokines secreted by BMDC differed among conditions. Asterisk denotes a significant (Tukey post-hoc test, p,0.05) elevation in
cytokine levels compared to all other conditions. MOMP & GL-vaults significantly increased CXCL10 levels ({; Tukey post-hoc test, p,0.01) compared
to media and empty vaults. Cell supernates were measured in triplicate.
doi:10.1371/journal.pone.0005409.g003
A Protective Vault Vaccine
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The internal cavity of the recombinant vault is large enough to
accommodate multiple proteins and we packaged the major outer
membrane protein (MOMP) of Chlamydia muridarum within
recombinant vaults. Chlamydial MOMP has immunogenic
properties and is able to lessen development of infertility after
Chlamydia infection [27,28]. MOMP (without its signal peptide)
was fused to the vault-targeting protein, mINT [3,17] (see
Materials and Methods). Purified cp-MVP-z/MOMP-mINT
vaults (illustrated schematically in Fig. 1b) were analyzed by
Western blot with an antibody specific for the VD1 portion of the
C. muridarium MOMP verifying that fusion of MOMP to the mINT
domain did not alter the ability of antibodies to recognize MOMP
(Fig. 1c). Negative stain EM of the cp-MVP-z/MOMP-mINT
showed that these vaults were indistinguishable from recombinant
cp-MVP vaults (Fig. 1d) and resembled native vaults [29].
Henceforth, we refer to these particles as MOMP-vaults.
Dendritic cell uptake and maturation by vaults
To investigate mechanisms whereby vaults interact with DC to
induce immunity, we compared the ability of immature BMDC to
incorporate GL-vaults and FITC-dextran using a standard uptake
assay [30]. Immature BMDC were produced from C57BL/6 mice
[31] and the maturity level measured by lack of cell surface
expressed MHC class II and other co-stimulatory molecules by
flow cytometry [19]. Immature BMDC (16106) were incubated
with media, GL-vaults or FITC-dextran for 30–60 minutes at
37uC and then stained for CD11c-PE, a cell surface marker of
murine DC. GL-vaults incubated with immature CD11c+ BMDC
for 30 minutes, resulted in lower levels of fluorescence compared
to FITC-dextran. However, at the longer exposure times (1 hr) the
rate of uptake was similar between GL-vaults and FITC-dextran
(Fig. 2a). A portion of the cells mixed with the green fluorescent
particles were fixed on poly-L-lysine coated slides to evaluate
particle incorporation. Our analysis showed that GL-vaults (green)
were internalized by CD11c+PE+ murine DC (red) and appeared
more concentrated in the cytoplasm compared to the FITC-
dextran control which mostly adhered to the cell surface (Fig. 2b).
This explained the observed kinetics, as FITC-dextran adherence
to the cell surface would saturate quickly and appear in the flow
cytometry experiments as increased uptake at an earlier time
Figure 4. Vaults do not stimulate toll receptors. Vaults were collected from sucrose gradient purification (fraction 40, 45 or a combination) and
sent to InvivoGen (San Diego, CA) for analysis of TLR stimulation. At least 10 mg of empty vaults (CPZ), GL-vaults (GL) or MOMP vaults (MOMP) were
incubated with NFkB reporter cells (2.5–5.06104 HEK 293) transfected with a single murine TLR (2, 3, 4, 5, 6, 7 or 9). Controls included TLR2 (heat-killed
Listeria monocytogenes, 108 cells/ml), TLR3 (Poly(I:C) 1 mg/ml), TLR4 (Escherichia coli K12 LPS, 100 ng/ml), TLR5 (S. typhimurium flagellin, 1 mg/ml),
TLR7 (Loxoribine, 1 mM), and TLR9 (CpG ODN 2006, 1 mg/ml). Secreted alkaline phosphatase (SEAP) activity was measured by absorbance detection.
Bars represent the mean absorbance of duplicate wells.
doi:10.1371/journal.pone.0005409.g004
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point. Thus, GL-vaults appear to be superior to FITC-dextran for
internalization.
Immature BMDC exposed to MOMP-vaults also secreted
cytokines and chemokines necessary for producing immune
responses. MOMP-vaults significantly increased the secretion of
a cytokine needed for production of Th1 cells (IL-12p70) compared
to empty vaults or the positive control, lipopolysaccharide (LPS)
(Fig. 3a). Increases in IL-12p70 were balanced by similar increases
in IL-10 secretion (Fig. 3b). In addition, MOMP-vaults also
significantly increased levels of CXCL10, a chemokine important
for attracting Th1 cells (Fig. 3c). Intriguingly, vaults containing
another protein, GL, but not empty vaults, also significantly
induced the maturation of BMDC by causing secretion of IL-
12p70, IL-10 and CXCL10 but not IL-4 (data not shown)
suggesting that vaults containing proteins favor induction of Th1
immune responses. Unexpectedly, protein-containing vaults did
not cause BMDC to secrete the pro-inflammatory cytokines
TNFa, IL-6 or CXCL2, a chemokine that attracts neutrophils and
a source of tissue inflammation (Fig. 3d–f) indicating that
immunization with vaults selectively reduces general inflammation
against a specific antigen.
Vaults do not activate any of the known murine Toll-like
receptors (TLR)
A common cause of cytokine production is ligation of TLR. To
determine if any of the known murine TLR are activated by vaults
we used an NFkB reporter assay. Various types of vaults (empty, GL
or MOMP) were collected from fractions of sucrose gradient
purification (fraction 40, 45 or a combination) and sent to InvivoGen
(San Diego, CA) for analysis of murine TLR stimulation. Different
gradient purified fractions were analyzed for each type of vault. To
our surprise, none of the known murine TLR (note that mice do not
have TLR8) produced alkaline phosphatase activity, a measure of
NFkB activation (Fig. 4). These results indicated that vaults did not
induce cytokine secretion from DC through TLR.
Protein-loaded vaults induce inflammasome activation
Although TLR are responsible for cytokine secretion by many
substances they are not responsible for cytokine production
induced by alum salts. The adjuvant alum is currently the only
FDA approved adjuvant employed in formulations of vaccines for
human use. Recently, the mechanism for inducing an adjuvant
effect by alum has been identified as inflammasome activation
[32,33]. To date, four different inflammasomes have been
characterized [34], containing the Nod-like receptors (NLR):
Nalp1, Nalp2, Nalp3 and Ipaf. Alum induces the oligomerization
of Nalp3, which in turn causes the recruitment of the adapter
protein, ASC (apoptosis-associated specklike protein containing a
caspase activation recruitment domain), to form a macromolecular
complex called an inflammasome. Two caspase-1 molecules are
then recruited and activated by the complex which then leads to
the activation of caspase-1 and subsequent IL-1b maturation.
We incubated immature BMDC with empty vaults, GL
containing or MOMP containing vaults for 6 hrs. Vaults
containing proteins but not empty vaults significantly increased
IL-1b levels in cell supernatants as measured by Luminex assay
(Fig. 5a). LPS by itself is capable of inducing low levels of IL-1b
secretion, but IL-1b secretion increased significantly when DC
cells were treated with LPS plus the ionophore nigericin (Nig),
which activates the Nalp3 inflammasome by inducing K+ efflux.
These results suggest that MOMP-vaults can both induce pro-IL-
1b synthesis and activate the inflammasome, resulting in the
maturation and secretion of increased levels IL-1b. This was
further confirmed by Western blot analysis showing that pro IL-1b
must first be induced by a stimulant, such as LPS, and then
cleaved by active caspase-1 produced from activated inflamma-
somes which causes disappearance of pro IL-1b (p37) in cell lysates
from GL, MOMP-vault and LPS+nigericin stimulated DC
(Fig. 5b). Note the appearance of a large band with approximate
weight of 100 kDa in the lanes containing vaults. This is likely due
to the z peptide of cp-MVP-z vaults binding antibody heavy chains
in the media. These data, taken together, suggest that cargo-
loaded vaults activate inflammasome formation and cause
secretion of IL-1b in a TLR-independent manner. Thus,
protein-containing vaults caused the maturation of DC which
produce cytokines for Th1 differentiation by activating inflamma-
somes and not TLR. Further, vaults do not cause DC to secrete
factors associated with tissue inflammation and are therefore
referred to as ‘‘smart adjuvants’’.
MOMP-vault intranasal immunization scheme
To determine if vault ‘‘smart adjuvants’’ containing MOMP
could induce mucosal immunity; we used the C. muridarum genital
infection model. Mice were immunized by delivering the
constructed vaults to the nasal mucosa at 2-wk intervals for a
Figure 5. Protein-containing vaults activate inflammasomes. (a)
BMDC (16106) were incubated with the indicated stimulates for 6 hrs
(media alone, 500 mg empty, GL-vaults or MOMP-vaults, 100 ng/ml LPS
alone or with 3.2 mM nigericin. The caspase-1 innhibitor, 20 mM z-YVAD-
fmk, was added to parallel wells containing 100 ng/ml of LPS and
3.2 mM nigericin. IL-1b was measured in triplicate supernatants by
Luminex. Bars represent mean IL-1b concentration of triplicates.
*p,0.001, compared to all conditions by ANOVA; #p,0.05, Tukey
post-hoc analysis comparing the level of IL-1b in supernatants of GL-
vault stimulated BMDC to that of supernatants from MOMP-vault
stimulated BMDC. (b) Western blot of BMDC cell lysates probed for
IL-1b.
doi:10.1371/journal.pone.0005409.g005
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total of three immunizations (Fig. 6a). This immunization
regimen was shown to reduce infection following intravaginal
challenge when soluble Chlamydia plus various adjuvants were
delivered together [21]. Mice immunized with 200 mg of
MOMP-vaults were estimated to contain approximately 0.2 mg
MOMP. As a negative control, mice were immunized i.n. with
200 mg GL-vaults [3] and as a positive immunization control
(Live-CM), mice were immunized i.n. with 16103 IFU of
chlamydiae [21]. Two weeks following the last vault immuniza-
tion or 4 weeks after the live lung infection, all mice were
hormonally synchronized by subcutaneous injection with me-
droxyprogesterone acetate to normalize infectivity. All mice were
challenged 1-wk later by intravaginal administration with
1.56105 IFU chlamydiae (Fig. 6a).
IgG responses after intranasal immunization with vault
nanoparticles
Serum antibody responses against chlamydiae were examined
to test the vault immunization scheme for development of
immunity. Sera were collected from mice 2 weeks after the last
immunization, pooled and analyzed by Western blot analysis. As
shown in Figure 6b, mice immunized with MOMP-vaults or Live
CM produced serum antibody against antigens found on
chlamydiae in contrast to mice immunized with the negative
control GL-vaults. Mice immunized with MOMP-vaults only
produced antibodies that bound to MOMP (MW 45 kDa) or
fragments of MOMP compared with the many proteins of
chlamydiae that were identified by mice given an i.n. infection
with C. muridarum. Thus, vaults designed for immunization were
capable of producing specific anti-chlamydial IgG.
Vaults are ubiquitous particles found in nearly all eukaryotic
cells and would not be expected to induce auto-antibodies [4]. The
vast majority (75%) of the vault mass consists of the major vault
protein (MVP) [5] and patients with a variety of autoimmune
diseases were not found to contain any immune reactivity against
MVP (data not shown). However, modifying vault design for
increased immunogenicity could possibly break tolerance to this
self protein and cause induction of specific antibody. We tested this
Figure 6. MOMP-vault immunization induces MOMP antibody. (a) C57BL/6 mice were vaccinated according to the indicated schedule and
the sera were collected 1 week after medroxyprogesterone acetate injection and right before genital infection. (b) Western blot reactivity of sera
pools from the indicated immunization group of mice blotted against a gel containing UV-inactivated, Renograffin gradient-purified chlamydiae
elementary bodies. Representative of two independent experiments. (c) ELISA assay of pooled sera against vault-coated plates. Bars represent the
mean of 4–6 mice per group and are representative of two independent experiments. * p,0.001, ANOVA. (d) Western blot reactivity of sera pools
from the indicated immunization groups or the rabbit monoclonal antibody against MVP blotted against a gel containing MOMP-vaults.
Representative of two independent experiments.
doi:10.1371/journal.pone.0005409.g006
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possibility using ELISA assays on individual sera and found that
MOMP-vault immunized mice developed significant antibody to
MVP (Fig. 6c). We confirmed this finding in serum pools of mice
using Western blot analysis of gels containing cp-MVP vaults. This
showed that mice infected i.n. with viable chlamydiae (Live CM)
did not produce IgG against vaults when reacted on membranes
containing MOMP-vaults (Fig. 6d). Likewise, immune sera from
mice immunized with GL-vaults did not produce IgG against
MVP (Fig. 6d), demonstrating that repeated i.n. administration of
vaults does not induce anti-vault antibody production when
designed with the z peptide to enhance development of immune
responses. Surprisingly, vaults containing the MOMP protein
which is similar in size to the GL-protein, did break tolerance to
this self protein and caused the formation of anti-vault antibodies
that reacted with the cp-MVP (Fig. 6d). Another fluorescent
protein, mCherry, was packaged into a cp-MVP-z vault and used
to immunize mice. Sera from these mice also did not produce
antibody to cp-MVP vaults by Western blot analysis (data not
shown). Thus, development of serum antibody to the vault self-
protein is a quality unique to MOMP and not all proteins induce
serum antibody formation to MVP.
MOMP-vault immunization protects against chlamydial
genital infection
The effect of immunization was first evaluated by monitoring
the bacterial burden in vaginal swabs collected every 3 days as
reported [20].Naı¨ve, non-immune C57BL/6 mice develop an
immune response against C. muridarum and typically clear a genital
infection 2–3-wks later [35] as was observed in mice given GL-
vaults (Fig. 7). In contrast, delivery of 200 mg MOMP-vaults
significantly reduced IFU levels isolated from vaginal swabs
compared to the group immunized with GL-vaults (Fig. 7). More
importantly, delivery of MOMP within vaults initially reduced
bacterial burden approximately 1 log lower than levels seen in
mice naturally immune from a lung infection with live chlamydiae
(Live CM) (Fig. 7). This was remarkable protection since in
previous studies only MOMP in the native conformation and not
recombinant MOMP could achieve this level of protection [36].
Also, a recent study using liposomes containing MOMP in its
native conformation as an immunogen followed by vaginal
challenge with the same amount of C. muridarum (16105 IFU)
did not reach the level of protection seen with MOMP-vault
immunization until 10 days after challenge [35]. These data
demonstrate that vaults containing MOMP induced a powerful
mucosal immunity in the absence of co-delivery with a cytokine
[37] or using a live microbial vector [38]. Hence, i.n. delivery of
MOMP-vaults was effective at inducing protective immunity as
demonstrated by reducing the magnitude of infection upon
intravaginal challenge with C. muridarum.
MOMP-vault immunization enhances Th1 cell immunity
in mucosal tissues
Inflammasome activation facilitates a strong adaptive immune
response and promotes the recruitment of immune cells to
mucosal tissues [39,40]. We evaluated Th1 cell immunity in
immunized mice after vaginal challenge by quantitating the
number of CD3+CD4+ cells that secrete IFNc or IL-4 (Fig. 8a) in
iliac lymph nodes (ILNs) during peak infection (day 7) and during
resolution of infection (day 15). MOMP-vault immunized mice
produced Th1 cells and demonstrated the migration of Th1 cells
by significantly altering the number of Th1 cells found in ILNs at
different times after challenge (Fig. 8b). In contrast, mice
immunized by a previous lung infection with C. muridarum had
similar numbers of Th1 cells in ILNs on days 7 and 15. (Fig. 8b).
All methods of inducing immunity produced a 10-fold greater
number of Th1 cells compared to Th2 cells in the ILNs on days 7
and 15 (Fig. 8c). In addition, we found a significant increase in a
cytokine associated with the presence of T cells (IL-1a) in oviduct
(OD) homogenates of MOMP-vault immunized mice as early as 7
days after challenge in comparison with immune mice given a lung
infection (Fig. 8d). This finding correlated with increased levels of
IFNc in these mice (Fig. 8e). Likewise, we also noted an increase in
the level of a chemokine associated with the recruitment of Th1
cells, CXCL10 (Fig. 8f). Taken together, these data indicate that
protein-containing vaults activate inflammasomes independently
of TLR. Inflammasome-activating agents in vivo are capable of
producing adaptive mucosal immunity which is characterized in
our system by specific antibody production, generation and
migration of Th1 cells and protective immunity from a mucosal
challenge infection. We hypothesize that protein-containing vaults
function as ‘‘smart adjuvants’’ by activating selective properties of
DC that stimulate adaptive mucosal immunity. Investigation of the
mechanism by which protein containing vaults stimulate mucosal
immunity would further development of vaccines.
Discussion
This study describes the first use of a novel vaccine platform for
producing effective cellular immune responses at mucosal surfaces.
Intranasal immunization using peptides contained within vault
nanoparticles allows development of immunity capable of
significantly limiting a bacterial infection in a mucosal tissue.
The vault design we employed for immunization was much more
effective at reducing bacterial burden following chlamydial genital
infection compared to a promising liposome preparation which
contains the same antigen (MOMP) and also uses a similar model
of chlamydial genital infection [35]. Moreover, immunization with
vault nanoparticles did not produce a pro-inflammatory cytokine
(TNFa) and a chemokine important for neutrophil recruitment
Figure 7. Immunization with MOMP-vaults reduces local
bacterial burden following genital infection. The bacterial burden
of chlamydiae following a challenge infection was determined from
vaginal swabs to be statistically reduced in the MOMP-vault immunized
group and the positive control group immunized i.n. with live C.
muridarum (Live CM) compared to the control GL-vault immunized
group (two-way RM ANOVA, *p,0.005). Dunn’s post-hoc test showed
no difference between the Live CM and the MOMP-vault immunized
groups.
doi:10.1371/journal.pone.0005409.g007
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(CXCL2). These results are consistent with the finding that vault
nanoparticles did not induce TLR stimulation since TNFa and
CXCL2 are produced following TLR stimulation. TLR stimula-
tion is associated with tissue inflammation and not pathogen
clearance during chlamydial genital infection [41]. Restraining
excess immune responses that are not necessary for eradicating
chlamydiae from the genital tract has been proposed to reduce
immune-mediated pathology and morbidity following C. trachomatis
STI [16,42]. These data indicate that vaults represent a novel
adjuvant for inducing protective immunity against microbial
infection at mucosal surfaces while limiting excess immunity and
investigation of this mechanism will advance vaccine research for
mucosal pathogens.
Inflammasome induction is important for producing adaptive
immune responses during influenza infection [43] and is
responsible for stimulating immune activation with the adjuvant,
alum [40]. Moreover, these studies both found that inflammasome
formation is required for leukocyte recruitment. Our data show
that vault immunization results in the production of factors
associated with increased lymphocyte recruitment such as
CXCL10 production. Further, vaults induced markedly higher
levels of IFNc, necessary for eradication of chlamydiae, soon after
infection in target tissue. Vaults are unique adjuvants that induce
activation of inflammasomes but do not stimulate through TLR.
Collectively, these results suggest that vaults are superior adjuvants
for immunization against infections largely limited to mucosal
tissues that rely on leukocyte recruitment for eradication.
The use of recombinant vaults as vaccine platforms to induce
immune responses to only the encapsulated protein and not the
vault protein appears to depend on the cargo within and not the
Figure 8. MOMP-vault immunization enhances the number and induces the redistribution of Th1 cells in the ILN. (a) Representative
histogram showing CD3+CD4+ cells and IFNc vs. IL-4 intracellular cytokine staining of ILN cells. The number of (b) Th1 or (c) Th2 cells in the ILNs of
individual mice on days 7 and 15 after challenge infection were compared by Students’ t-test (*p,0.02). Representative experiment with 4–5 mice
per group where at least 50,000 cells were analyzed per mouse. The level of (d) IL-1a, (e) IFNc, and (f) CXCL10 was measured in triplicate in OD tissue
homogenates at two time-points after challenge infection in mice immunized with MOMP-vaults or given a lung infection with C. muridarum using
Luminex assays (Milipore Corp). Cytokine levels were compared by Students’ t-test (*p,0.05). One representative experiment of 3–5 mice per group.
doi:10.1371/journal.pone.0005409.g008
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general use of vaults. Intriguingly, we find that the inclusion of
MOMP in vaults was able to break tolerance to this self protein
and induce anti-MVP IgG. In contrast, mice exposed to vaults
containing other proteins GL or mCherry (data not shown), did
not produce antibody to MVP yet could induce maturation of
dendritic cells. MOMP has not been reported to induce antibodies
that also cross react against host proteins. However, MOMP-vault
exposure induced significantly greater levels of IL-1b than GL-
vaults indicating that the full length sequence of MOMP within
vaults enhances inflammasome formation, possibly as consequence
of the porin function or the ability to boost pro-IL-1b. Thus, the
degree of inflammasome induction appears to correlate with
generation of functional adaptive immune responses. Perhaps
development of antibodies to MVP may serve as a screening assay
to differentiate the pool of vaccine candidates. The creation of a
vault containing appropriate immunogenic peptides that do not
break tolerance to self-proteins is the next step for utilizing this
effective yet simplistic system for inducing anti-microbial immu-
nity at mucosal surfaces. The ideal vaccine platform would be a
‘‘smart adjuvant’’ that could deliver an antigen to mucosal surfaces
and induce rapid anti-microbial immunity while at the same time
safeguarding the function of delicate mucosal surfaces by limiting
the inflammatory response. Our data indicate that vaults
engineered to deliver antigens may in fact act as ‘‘smart adjuvants’’
directing Th1 mediated immunity in mucosal tissues without
inducing excessive inflammation.
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